(PRWEB) April 18, 2013
The North America Injectable Drug Delivery Market by Formulations [Liposomes, Microspheres, & Nanoparticles], Devices [Disposables & Reusable, Fillable & Prefilled, Pen, Needle Free & Auto Injectors] & Therapeutics [Diabetes & Oncology] Forecasts to 2017, analyzes and studies the major market drivers, restraints, and opportunities in United States and Canada.
130 Market Data Tables
280 Pages and an in-depth Table of Content on North America Injectable Drug Delivery Market.
Early buyers will receive 10% customization on this report.
The North American injectable drug delivery technologies market was valued at $ 9.3 billion in 2012 and is poised to grow at a CAGR of 12.3% from 2012 to 2017 to reach $ 16.6 billion by 2017.
The North America Injectable Drug Delivery Market is broadly categorized into two major segments, namely, devices technologies and formulation technologies. Based on products, the injectable drug delivery devices technologies market is further categorized into conventional injection devices, self injection devices, and others (micro needles, nano needles and blunt needle injections), while the injectable drug delivery formulation technologies market is categorized into conventional drug delivery formulations and novel drug delivery formulations. The conventional injection devices segment accounted for the largest share of the overall injectable drug delivery technologies market in 2012.
In addition, the market is segmented on the basis of its therapeutic applications such as auto immune diseases, hormonal imbalances, oncology, orphan/rare diseases (Hemophilia, Ribose-5-phosphate isomerase deficiency (RPI deficiency), Cystic Fibrosis, and Wilsons disease) and others (pain management, allergies, hepatitis C, and aesthetic treatment). Hormonal disorders commanded the largest share of the global injectable drug delivery technologies market in 2012.
The Major Markets covered in this report are United States and Canada. The United States accounted for the largest market of the North American injectable drug delivery technologies market in the year 2012. The growth of the injectable drug delivery technologies market is primarily triggered by innovations in injectable drug delivery devices, the surge of biologics, rising prevalence of diabetes in the U.S. and Canada, improvement in patient compliance and incessant rise in partnerships, collaborations and acquisitions among prominent players in this market. However, factors such as product recalls, stringent regulatory systems and needle-stick injuries and infections are restraining the growth of the market.
The report includes company profiles of major players such as Eli Lilly & Co. (U.S.), Sanofi (France), Novo Nordisk A/S (Denmark), Baxter International, Inc. (U.S.), Becton Dickinson & Co. (U.S.), and Hospira Inc. (U.S.). Other prominent players in North America are West Pharmaceutical Services, Inc. (U.S.), Unilife Corporation (U.S.), Antares Pharma, Inc. (U.S.), and Zogenix, Inc. (U.S.), among others.
Buy a copy of this report @ http://www.marketsandmarkets.com/Purchase/purchase_report1.asp?id=1109
Find related Reports at – Biotechnology Market
MarketsandMarkets is a global market research and consulting company based in the U.S. We publish strategically analyzed market research reports and serve as a business intelligence partner to Fortune 500 companies across the world.
MarketsandMarkets also provides multi-client reports, company profiles, databases, and custom research services. MarketsandMarkets covers thirteen industry verticals, including advanced materials, automotive and transportation, banking and financial services, biotechnology, chemicals, consumer goods, energy and power, food and beverages, industrial automation, medical devices, pharmaceuticals, semiconductor and electronics, and telecommunications and IT.
North – Dominion Plaza,
17304 Preston Road,
Suite 800, Dallas, TX 75252
Connect with us on LinkedIn
Connect with us on Facebook